Contract services for biologics evolve | August 21, 2017 Issue - Vol. 95 Issue 33 | Chemical & Engineering News
Volume 95 Issue 33 | pp. 34-35
Issue Date: August 21, 2017 | Web Date: August 20, 2017

Contract services for biologics evolve

As the drug pipeline fills with large molecules, contractors add to customer offerings
Department: Business
Keywords: Outsourcing, biologics, research, development, acquisition, manufacturing

Approximately half the drugs in the pharmaceutical pipeline now are biologics, a statistic that reflects the drug industry’s shift in emphasis over the past two decades from small to large molecules. In that time, drug firms outsourced much of their small-molecule research, development, and manufacturing operations and invested heavily in biologics. The small-molecule drug services sector, meanwhile, consolidated to create a business populated by what is known as contract development and manufacturing organizations, or CDMOs.

. . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society